Abstract
Ki67 immunohistochemistry (IHC) with a cut-off of 20% by MIB-1 PharmDx assay has been approved as a companion diagnostic for adjuvant abemaciclib in high-risk ER+HER2- breast cancer. We addressed the genomic risk profile of high Ki67 (≥20%) ER+HER2- breast cancer using a 21-gene multigene assay (Oncotype DX test). In addition, we investigated survival outcomes and identified factors associated with low genomic risk in the high Ki67 group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
